Having trouble viewing this email? Click here

white ribbonOncimmunewhite ribbon
 

Want to learn more?

Contact Us

Oncimmune

Client Services

1-888-583-9030

clientservices@oncimmune.com

Quick Links
Join Our List

Join Our Mailing List
As reported in The New York Times, "Lung Cancer Deaths are Reduced by CT Scans."  The challenge with CT, as reported in recent NCI data, is the 25 percent false positive rate.  

 

EarlyCDT™-Lung is a blood test which can be used in congruence with CT to aid in risk assessment and early detection of lung cancer in high-risk patients or patients with a lung nodule under surveillance; a positive result can increase malignancy risk by 5-fold.

 

Benefits of EarlyCDT™-Lung:

·        3 times better Positive Predictive Value than CT

·        7 times fewer false positives than CT

·       Detects all types and all stages of lung cancer, including Stage 1

·       Is reimbursed by Medicare Part B and private insurance 

Learn more about EarlyCDT™-Lung

EarlyCDT™-Lung is a simple blood test based on a panel of autoantibodies, which arise early in the development of lung cancer.

  

To bring more recognition to November, National Lung Cancer Awareness Month, Oncimmune released Hello, Have You Heard?, a reliable source of information for your patients. The site provides current information on lung cancer, early detection and other related topics. 

 
Safe Unsubscribe
This email was sent to clientservices@oncimmune.com by clientservices@oncimmune.com.

Oncimmune | 8960 Commerce Drive | Building 6 | De Soto | KS | 66018

 

 

blogger statistics

 


 

 

This is one of the types of email ads that you can market here at www.iomegaone.com